Top Most 14+ Apto-cg-806-01

1.A Study Of CG-806 In Patients With Relapsed Or Refractory CLL/SLL ...
$A Study Of CG-806 In Patients With Relapsed Or Refractory CLL/SLL ...$
28 mars 2019 · Aptose Biosciences Inc. ClinicalTrials.gov Identifier: NCT03893682 History of Changes. Other Study ID Numbers: APTO-CG-806-01.

View more »
2.A Study Of CG-806 In Patients With Relapsed Or Refractory AML Or ...
$A Study Of CG-806 In Patients With Relapsed Or Refractory AML Or ...$
20 juil. 2020 · Acute Myeloid Leukemia Myelodysplastic Syndromes, Drug: CG-806, Phase 1 ... This is a multicenter, open-label, Phase 1 a/b dose escalation ...

View more »
3.Aptose Doses First CLL Patient In Phase 1 Study Of CG-806 And ...

16 juil. 2019 · CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor and is in a Phase 1 clinical trial for the treatment of ...

View more »
4.Luxeptinib For CLL & NHL - Aptose Biosciences Inc.

Aptose Biosciences is sponsored a phase 1 a/b trial to assess the safety of CG-806 in patients with CLL/SLL or non-Hodgkin's lymphomas.

View more »
5.Aptose Presents New Preclinical Data On CG-806 And APTO-253

1 avr. 2019 · CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor and is in a Phase 1 clinical trial for hematologic ...

View more »
6.Aptose Presents Early Phase 1a/b CG-806 Clinical Findings

12 juin 2020 · SAN DIEGO and TORONTO, June 12, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a ...

View more »
7.FDA Allows Human Trials Of Aptose's CG-806 Oral Compound For AML

9 juil. 2020 · CG-806 is currently being tested in a Phase 1 dose escalation study ... study (NCT02267863) for an alternative therapy called APTO-253 in ...

View more »
8.CG'806, A First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits ...

29 nov. 2018 · Whereas 0.1 µM and 1 µM CG'806 caused about 25% and 45% apoptotic cell death, respectively, 1 µM ibrutinib induced less than 10% cell death ...

View more »
9.Luxeptinib - Aptose Biosciences/CrystalGenomics - AdisInsight

Luxeptinib (formerly CG 806) is an orally administered, small molecule, pan-Bruton's ... or non-Hodgkin's lymphoma patients (APTO-CG-806-01; NCT03893682).

View more »
10.CG-806 For Relapsed Or Refractory CLL/SLL Or Non-Hodgkin's ...
$CG-806 For Relapsed Or Refractory CLL/SLL Or Non-Hodgkin's ...$
Clinical Trial Information. Trial Contact: Donaldson, Karin M; Frankos, Marie; Grofsik, Kiera · IRB No: WIRB 20190544. Protocol Abbrev: TRIO APTO-CG-806-01.

View more »
11.18281-Waldenström Macroglobulinemia-NA-596

A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas (APTO-CG-806-01). Details.

View more »
12.A Study Of CG-806 In Patients With Relapsed Or Refractory CLL/SLL ...
$A Study Of CG-806 In Patients With Relapsed Or Refractory CLL/SLL ...$
The purpose of this study is to evaluate the safety, tolerability and effectiveness of CG-806 for the treatment of patients with the condition of chronic ...

View more »
13.BRIEF-Aptose Prioritizes Development Of CG'806 First-in Class FLT3 ...

23 janv. 2017 · Will prioritize resources toward development of CG'806 for patients ... clinical activities with APTO-253, a Phase 1 stage compound for AML.

View more »
14.Aptose Prioritizes Development Of CG'806 First-in Class FLT3/BTK ...

23 janv. 2017 · activities with APTO-253, a phase 1 stage compound for AML, ... established CG'806 as a well-differentiated pan-FLT3 inhibitor that ...

View more »

Contact